IEO Webcast – The value of HPV DNA testing in the fight against cervical cancer
“Since the 1970s, screening for cervical cancer has been carried out by cytological examination. In 2012, the Health Technology Assessment report made public the fact that HPV-based screening tests validated as first-line tests could be more effective than cytology-based screening in the prevention of invasive cervical cancer. In 2013, European guidelines, adopted in Italy through the Ministry of Health guidance document, sanctioned the use of HPV testing as the primary test to be used in screening for cervical cancer, which then left cytology to play the role of triage for positive HPV tests. This was because it emerged from the literature data that the sensitivity of the HPV Test was considerably more effective than cervical screening, which nevertheless remains a good triage test because of its high specificity.”-Dr. Fabio Bottari (IEO).
To better understand the evolution of HPV diagnosis and screening, the central role of anatomical pathology laboratories, which strategies are now available to health care practitioners in the fight against cervical cancer and how effective they are, we interviewed Dr. Fabio Bottari and Dr. Anna Daniela Iacobone of the European Institute of Oncology (IEO) over the course of 3 episodes.
First Episode – Dr. Fabio Bottari – Available HPV tests and their value to the laboratory
Second Episode – Dr. Anna Daniela Iacobone – The value of HPV testing in the prevention of cervical cancer, “Value for the Gynaecologist”
Third Episode – Dr. Anna Daniela Iacobone & Dr. Fabio Bottari – The added value of SELF-SAMPLING for HPV testing in the prevention of cervical cancer
BD-69834
BD-73005
